Description
An anticancer celecoxib derivative; does not inhibit COX-2 (IC50 = >100 µM); inhibits mPGES-1 in HeLa cells (IC50 = 15.6 µM); reduces PGE2 production in HeLa, A549, and HCA-7 cells (IC50s = 0.64, 0.83, and 3.08 µM, respectively); inhibits proliferation of drug-sensitive RPMI8226 and multidrug-resistant 8226/Dox40 multiple myeloma cells; increases the rate of apoptosis in RPMI8226 and 8226/Dox40 cells at 20 and 30 µM; the antiproliferative effect of 2,5-dimethyl celecoxib is independent of mPGES-1 inhibition
Formal name: 4-[5-(2,5-dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide
Synonyms: DMC
Molecular weight: 395.4
CAS: 457639-26-8
Purity: ≥95%
Formulation: A solid
Product Type|Biochemicals|Small Molecule Inhibitors|Prostaglandin Synthases||Research Area|Cancer|Cell Cycle||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Cancer|Multidrug Resistance||Research Area|Lipid Biochemistry